Document Detail


Treating fatigue.
MedLine Citation:
PMID:  17686346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fatigue is recognized as one of the most disabling and common symptoms of MS. However, no universal consensus has been reached regarding a formal definition for fatigue, and its mechanisms and causes are not understood. This review summarizes important research in this field and recommends a multidisciplinary approach to managing MS patients with fatigue. Such an approach should include proven pharmaceutical and non-pharmaceutical treatments.
Authors:
Y Lapierre; S Hum
Related Documents :
2481176 - Ten years of clinical experience with metoprolol.
12746036 - Tobacco counter-advertising: a review of the literature and a conceptual model for unde...
17652236 - Tobacco industry lawyers as "disease vectors".
24229066 - The dsm-5 - an interview with david kupfer.
18229556 - A research note on the levinson and sanford anti-semitism scale.
22160786 - Partnerships for the design, conduct, and analysis of effectiveness, and implementation...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  International MS journal / MS Forum     Volume:  14     ISSN:  1352-8963     ISO Abbreviation:  Int MS J     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-08-09     Completed Date:  2007-10-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9804403     Medline TA:  Int MS J     Country:  England    
Other Details:
Languages:  eng     Pagination:  64-71     Citation Subset:  IM    
Affiliation:
Montreal Neurological Hospital/Institute, 3801 University, Montreal, Quebec, Canada H3A 2B4.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amantadine / therapeutic use*
Central Nervous System Stimulants / therapeutic use*
Comorbidity
Diagnosis, Differential
Dopamine Agents / therapeutic use*
Evidence-Based Medicine
Fatigue / drug therapy,  etiology,  therapy*
Humans
Multiple Sclerosis / physiopathology*
Patient Care Team
Pemoline / therapeutic use*
Chemical
Reg. No./Substance:
0/Central Nervous System Stimulants; 0/Dopamine Agents; 2152-34-3/Pemoline; 768-94-5/Amantadine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Confirming the MS diagnosis.
Next Document:  Intravenous ketamine attenuates injection pain and arterial pressure changes during the induction of...